BRUIN CLL-322 is EHA 2026 LB5001, a Phase 3 trial of fixed-duration pirtobrutinib plus venetoclax-rituximab…
Browsing: biotech analysis
Incyte maintained a strong presence at EHA 2026, presenting clinical advances across hematologic malignancies and…
Caribou Biosciences maintained a growing presence at EHA 2026, presenting advances in CRISPR genome-edited allogeneic…
Kura Oncology maintained a notable presence at EHA 2026, presenting clinical advances in precision-targeted therapies…
Roche and Genentech maintained a strong presence at EHA 2026, presenting a broad portfolio of…
Genmab and AbbVie maintained a strong presence at EHA 2026, presenting clinical advances in antibody-based…
Regeneron maintained a strong presence at EHA 2026, presenting clinical advances across hematologic malignancies with…
Pfizer maintained a strong presence at EHA 2026, presenting clinical advances across hematologic malignancies with…
GSK maintained a strong scientific presence at EHA 2026, presenting clinical advances across hematologic malignancies…
Nurix Therapeutics maintained a growing presence at EHA 2026, presenting advances in targeted protein degradation…